TG Therapeutics Reports Q3 Revenue Beat and Raises Full-Year 2026 Guidance
TG Therapeutics (TGTX) reported third-quarter revenue of $259.9 million, representing a 60.7% increase year-over-year and exceeding analyst expectations by $14.45 million. While GAAP earnings per share (EPS) of $0.35 slightly missed consensus estimates by $0.01, the company's strong top-line performance was driven largely by BRIUMVI sales. Following these results, the company raised its full-year 2026 total global revenue guidance to approximately $1 billion, up from the previous estimate of $950 million. Additionally, BRIUMVI U.S. net product revenue guidance was increased to a range of $915–$920 million. The market responded positively to the strengthened outlook, with shares rising 7% in after-hours trading.
Tickers: $TGTX
Topics: biotechnology earnings_miss guidance_upgrade revenue_beat
Read the full article at Seeking Alpha
Part of the story AAON Shares Surge 22% Following Third-Quarter Earnings Beat and Raised Full-Year Guidance (29 articles)